# Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

> **NCT06872684** · NA · RECRUITING · sponsor: **Stryker Neurovascular** · enrollment: 183 (estimated)

## Conditions studied

- Aneurysm
- Aneurysm, Intracranial

## Interventions

- **DEVICE:** Surpass Elite with Guardian Flow Diverter System

## Key facts

- **NCT ID:** NCT06872684
- **Lead sponsor:** Stryker Neurovascular
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2029-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06872684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06872684, "Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06872684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*